Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 326

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

Open access
Hashimoto, Masao, Araki, Koichi, Cardenas, Maria A., Li, Peng, Jadhav, Rohit R., Kissick, Haydn T., Hudson, William H., McGuire, Donald J., Obeng, Rebecca C., Wieland, Andreas, Lee, Judong, McManus, Daniel T., Ross, James L., Im, Se Jin, Lee, Junghwa, Lin, Jian-Xin, Hu, Bin, West, Erin E., Scharer, Christopher D., Freeman, Gordon J., Sharpe, Arlene H., Ramalingam, Suresh S., Pellerin, Alex, Teichgräber, Volker, Greenleaf, William J., Klein, Christian, Goronzy, Jorg J., Umaña, Pablo, Leonard, Warren J., Smith, Kendall A., Ahmed, Rafi·2022·Nature

Abstract

Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic lymphocytic choriomeningitis virus infection 1 . Here we examine the underlying basis for this synergy. We show that PD-1 + IL-2 combination therapy, in contrast to PD-1 monotherapy, substantially changes the differentiation program of the PD-1 + TCF1 + stem-like CD8 + T cells and results in the generation of transcriptionally and epigenetically distinct effector CD8 + T cells that resemble highly functional effector CD8 + T cells seen after an acute viral infection. The generation of these qualitatively superior CD8 + T cells that mediate viral control underlies the synergy between PD-1 and IL-2. Our results show that the PD-1 + TCF1 + stem-like CD8 + T cells, also referred to as precursors of exhausted CD8 + T cells, are not fate-locked into the exhaustion program and their differentiation trajectory can be changed by IL-2 signals. These virus-specific effector CD8 + T cells emerging from the stem-like CD8 + T cells after combination therapy expressed increased levels of the high-affinity IL-2 trimeric (CD25–CD122–CD132) receptor. This was not seen after PD-1 blockade alone. Finally, we show that CD25 engagement with IL-2 has an important role in the observed synergy between IL-2 cytokine and PD-1 blockade. Either blocking CD25 with an antibody or using a mutated version of IL-2 that does not bind to CD25 but still binds to CD122 and CD132 almost completely abrogated the synergistic effects observed after PD-1 + IL-2 combination therapy. There is considerable interest in PD-1 + IL-2 combination therapy for patients with cancer 2 , 3 , and our fundamental studies defining the underlying mechanisms of how IL-2 synergizes with PD-1 blockade should inform these human translational studies. PD-1 + TCF1 + stem-like CD8 + T cells—precursors of exhausted CD8 + T cells—are not fate-locked into the exhaustion program; their differentiation trajectory can be changed by IL-2 signals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-05257-0

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 326

Metadata

Authors
Hashimoto, M., Araki, K., Cardenas, M. A., Li, P., Jadhav, R. R., Kissick, H. T., Hudson, W. H., McGuire, D. J., Obeng, R. C., Wieland, A., Lee, J., McManus, D. T., Ross, J. L., Im, S. J., Lee, J., Lin, J.-X., Hu, B., West, E. E., Scharer, C. D., Freeman, G. J., Sharpe, A. H., Ramalingam, S. S., Pellerin, A., Teichgräber, V., Greenleaf, W. J., Klein, C., Goronzy, J. J., Umaña, P., Leonard, W. J., Smith, K. A., & Ahmed, R.
Venue
Nature
Published
2022-09-28
Volume
610
Issue
7930
Pages
173-181
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4297497801
Cited by
326
References
55
FWCI
20.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. https://app.cochat.ai/papers/10.1038/s41586-022-05257-0
The paper
Hashimoto, M., Araki, K., Cardenas, M. A., Li, P., Jadhav, R. R., Kissick, H. T., Hudson, W. H., McGuire, D. J., Obeng, R. C., Wieland, A., Lee, J., McManus, D. T., Ross, J. L., Im, S. J., Lee, J., Lin, J.-X., Hu, B., West, E. E., Scharer, C. D., . . . Ahmed, R. (2022). PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. https://doi.org/10.1038/s41586-022-05257-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.